--- title: "Morning Trend | JACOBIO-B reduces volume and grinds at the bottom, will an upward opportunity emerge?" type: "News" locale: "en" url: "https://longbridge.com/en/news/273347878.md" description: "JACOBIO-B (1167.HK) consolidated with reduced volume yesterday, with the stock price operating within a limited range, repeatedly testing the resistance at HKD 8.08 without success. The biopharmaceutical sector is still in a high valuation correction phase, and overall market risk appetite has declined. The company has had no significant new drug development or financing movements in the past two weeks, leading to a cautious stance among main investors, focusing on range trading and active arbitrage. Although acquisition news in the sector has attracted attention, the effect has not transmitted to JACOBIO. The technical chart shows a continuation of the MACD death cross, with short-term moving averages trending downward and selling pressure persisting. If there is a rebound, trapped positions at high levels may actively seek to break even, making the market prone to repeated washout characteristics. In the short term, if there are clinical news on new drugs or industry mergers, it may ignite sentiment; otherwise, right-side capital operations need to remain cautious, and risk exposure must be strictly controlled. Aggressive accumulation is not recommended without strong signals" datetime: "2026-01-23T01:00:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/273347878.md) - [en](https://longbridge.com/en/news/273347878.md) - [zh-HK](https://longbridge.com/zh-HK/news/273347878.md) --- # Morning Trend | JACOBIO-B reduces volume and grinds at the bottom, will an upward opportunity emerge? JACOBIO-B (1167.HK) consolidated with reduced volume yesterday, with the stock price range limited and the pressure at HKD 8.08 tested multiple times without success. The biopharmaceutical sector is still in a high valuation correction phase, and overall market risk appetite has declined. The company has had no significant new drug development or financing movements in the past two weeks, leading to a cautious stance from main investment forces, with range trading and active arbitrage being the focus. Although acquisition news in the sector has attracted attention, the effect has not transmitted to JACOBIO. The technical chart shows a continuation of the MACD death cross, with short-term moving averages trending downward and selling pressure persisting. If there is a rebound, trapped positions at high levels may actively seek to break even, making the market prone to repeated washout characteristics. In the short term, if there are new drug clinical news or industry mergers and acquisitions, it may ignite sentiment; otherwise, right-side capital operations need to remain cautious, and risk exposure must be strictly controlled. Aggressive accumulation is not recommended without strong signals ### Related Stocks - [513700.CN](https://longbridge.com/en/quote/513700.CN.md) - [159506.CN](https://longbridge.com/en/quote/159506.CN.md) - [516500.CN](https://longbridge.com/en/quote/516500.CN.md) - [01167.HK](https://longbridge.com/en/quote/01167.HK.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [159892.CN](https://longbridge.com/en/quote/159892.CN.md) - [513120.CN](https://longbridge.com/en/quote/513120.CN.md) - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) - [588130.CN](https://longbridge.com/en/quote/588130.CN.md) - [520690.CN](https://longbridge.com/en/quote/520690.CN.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [520500.CN](https://longbridge.com/en/quote/520500.CN.md) - [159570.CN](https://longbridge.com/en/quote/159570.CN.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) ## Related News & Research - [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md) - [Jacobio Boosts Share Buybacks and Liquidity as Oncology Pipeline Advances](https://longbridge.com/en/news/286835606.md) - [Everest Medicines Director and Major Shareholder Raises Stake in Company](https://longbridge.com/en/news/286481551.md) - [Wuxi AppTec to Raise Around $1 Billion Through Zero Coupon Convertible Bonds](https://longbridge.com/en/news/286487023.md) - [Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended](https://longbridge.com/en/news/286268861.md)